Safety and benefits of protamine administration to revert anticoagulation soon after coronary angioplasty. A meta-analysis

Journal of Thrombosis and Thrombolysis

Volumn 30, Issue 4, 2010, Pages 452-458

  De Luca, Giuseppe ^a   Parodi, Guido ^b   Antoniucci, David ^b  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Bleeding complications; Coronary angioplasty; Protamine administration

Indexed keywords

ANTICOAGULANT AGENT; PROTAMINE;

ARTICLE; DRUG ANTAGONISM; HUMAN; META ANALYSIS; METHODOLOGY; MORTALITY; POSTOPERATIVE HEMORRHAGE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, BALLOON, CORONARY; ANTICOAGULANTS; HUMANS; POSTOPERATIVE HEMORRHAGE; PROTAMINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80053375761     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-010-0482-4     Document Type: Article

References (21)

1. De Luca G, Stone GW, Suryapranata H et al (2009) Efficacy and safety of drug-eluting stents in ST-segment elevation myocardial infarction: A meta-analysis of randomized trials. Int J Cardiol 133:213-222
2. Mehran R, Pocock SJ, Stone GW, Clayton TC, Dangas GD, Feit F, Manoukian SV, Nikolsky E, Lansky AJ, Kirtane A, White HD, Colombo A, Ware JH, Moses JW, Ohman EM (2009) Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: A risk model from the ACUITY trial. Eur Heart J 30:1457-1466
3. Jaques LB (1973) Protamine antagonist to heparin. J Can Med Assoc 108:1291-1297
4. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF (1999) Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Quality of reporting of meta-analyses. Lancet 354:1896-1900
5. Pan M, Suarez de Lezo J, Medina A, Romero M, Hernandez E, Segura J, Melian F, Wanguemert F, Landin M, Benitez F, Amat M, Velasco F, Torres A (1997) In-laboratory removal of femoral sheath following protamine administration in patients having intra-coronary stent implantation. Am J Cardiol 80:1336-1338
6. Ducas J, Chan MC, Miller A, Kashour T (2002) Immediate protamine administration and sheath removal following percutaneous coronary intervention: A prospective study of 429 patients. Catheter Cardiovasc Interv 56:196-199
7. Briguori C, Di Mario C, De Gregorio J, Sheiban I, Vaghetti M, Colombo A (1999) Administration of protamine after coronary stent deployment. Am Heart J 138:64-68
8. Parodi G, De Luca G, Moschi G et al. (2010) Safety of immediate reversal of anticoagulation by protamine to reduce bleeding complications after infarct artery stenting for acute myocardial infarction and adjunctive abciximab therapy. J Thromb Thrombolysis (in press)
9. Thuesen L, Andersen HR, Bøtker HE, Dalby Kristensen S, Krusell LR, Lassen JF (2005) In-laboratory femoral sheath removal after heparin reversal by protamine after percutaneous coronary intervention. EuroIntervention 1:66-69
10. Parodi G, Migliorini A, Valenti R, Bellandi B, Signorini U, Moschi G, Buonamici P, Cerisano G, Antoniucci D (2010) Comparison of bivalirudin and unfractionated heparin plus protamine in patients with coronary heart disease undergoing percutaneous coronary intervention (from the antithrombotic regimens and outcome [ARNO] trial). Am J Cardiol 105:1053-1059
11. Kaneda H, Suzuki J, Hosokawa G et al (2005) Impact of heparin neutralization by protamine on restenosis after coronary stent implantation. Int J Cardiol 105:111-112
12. Rossi ML, Zavalloni D, Scatturin M, Gasparini GL, Lisignoli V, Presbitero P (2007) Immediate removal of femoral-sheath following protamine administration in patients undergoing intracoronary paclitaxel-eluting-stent implantation. Expert Opin Pharmacother 8:2017-2024
13. Kereiakes DJ, Broderick TM, Whang DD, Anderson L, Fye D (1997) Partial reversal of heparin anticoagulation by intravenous protamine in abciximab-treated patients undergoing percutaneous intervention. Am J Cardiol 80:633-634
14. Lohne F, Kløw NE, Stavnes S, Brekke M, Hoffmann P, Stensaeth KH, Søvik E, Pettersen MS (2004) Safety of heparin reversal with protamine and immediate sheath removal after coronary angioplasty. Acta Radiol 45:171-175
15. Agostoni P, Biondi-Zoccai GG, de Benedictis ML, Rigattieri S, Turri M, Anselmi M, Vassanelli C, Zardini P, Louvard Y, Hamon M (2004) Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures; systematic overview and meta-analysis of randomized trials. J Am Coll Cardiol 44:349-356
16. Stone GW, Bertrand M, Colombo A, Dangas G, Farkouh ME, Feit F, Lansky AJ, Lincoff AM, Mehran R, Moses JW, Ohman M, White HD (2004) Acute catheterization and urgent Intervention triage strategy (ACUITY) trial: Study design and rationale. Am Heart J 148:764-775
17. Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW, HORIZONS-AMI Trial Investigators (2009) Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 374:1149-1159
18. Horrow JC (1985) Protamine: A review of its toxicity. Anesth Analg 64:348-361
19. Click RL, Hamburger HA, Bove AA (1989) Complement activation from protamine sulfate after coronary angiography. Catheter Cardiovasc Diagn 16:221-225
20. Evora PRB, Pearson PJ, Schaff HV (1995) Protamine indices endothelium dependent vasodilatation of the pulmonary artery. Ann Thorac Surg 60:405-410
21. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, TRITON-TIMI 38 Investigators (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001-2015